Loading…
Loading…
See exactly how FBT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for FBT and 80,000+ other tickers.
The First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund (ETF) designed with a clear purpose: to accurately reflect the price movements and income generated by the NYSE Arca Biotechnology Index. Its core objective is to closely match the performance of this benchmark index, before accounting for the fund's operational fees and expenses.
FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.
iShares Global Healthcare ETF provides broad exposure to 110 global stocks while First Trust NYSE Arca Biotechnology Index Fund concentrates on 30 biotech positions. iShares Global Healthcare ETF carries a lower expense ratio of 0.40% compared to 0.55% for First Trust NYSE Arca Biotechnology Index Fund.
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
First Trust NYSE Arca Biotechnology Index Fund offers a more concentrated portfolio with only 30 holdings compared to the 248 positions in iShares Biotechnology ETF iShares Biotechnology ETF is the larger and more established fund, having launched in 2001 and managing $9.6 billion in assets under management First Trust NYSE Arca Biotechnology Index Fund has achieved a higher total return over both one-year and five-year horizons
A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market.